Log in

NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

$79.34
+4.78 (+6.41 %)
(As of 03/31/2020 01:57 AM ET)
Today's Range
$78.47
Now: $79.34
$84.40
50-Day Range
$62.82
MA: $80.76
$89.66
52-Week Range
$61.61
Now: $79.34
$92.45
Volume47.13 million shs
Average Volume12.00 million shs
Market Capitalization$139.91 billion
P/E Ratio38.51
Dividend Yield1.93%
Beta1.17
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Read More
Abbott Laboratories logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$5.31 per share
Book Value$17.70 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Employees107,000
Outstanding Shares1,763,430,000
Market Cap$139.91 billion
Next Earnings Date4/16/2020 (Confirmed)
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABT shares have increased by 1.6% and is now trading at $79.34. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 16th 2020. View our earnings forecast for Abbott Laboratories.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Thursday, April 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, January, 22nd. The healthcare product maker reported $0.95 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.39%. Abbott Laboratories's revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.81 earnings per share. View Abbott Laboratories' earnings history.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 21st. Investors of record on Wednesday, April 15th will be paid a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date of this dividend is Tuesday, April 14th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' dividend history.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.60.

What price target have analysts set for ABT?

17 brokers have issued 12-month price objectives for Abbott Laboratories' stock. Their forecasts range from $81.00 to $105.00. On average, they expect Abbott Laboratories' stock price to reach $95.36 in the next year. This suggests a possible upside of 20.2% from the stock's current price. View analysts' price targets for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News stories about ABT stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of -3.7 on InfoTrie's scale. They also gave headlines about the healthcare product maker a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutAbbott Laboratories.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a increase in short interest in March. As of March 13th, there was short interest totaling 23,053,500 shares, an increase of 21.5% from the February 27th total of 18,970,000 shares. Based on an average daily trading volume, of 5,550,000 shares, the short-interest ratio is currently 4.2 days. Approximately 1.3% of the shares of the stock are sold short. View Abbott Laboratories' Current Options Chain.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Walt Disney (DIS), NVIDIA (NVDA), Home Depot (HD), Pfizer (PFE), Verizon Communications (VZ) and Intel (INTC).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $79.34.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $139.91 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe. View additional information about Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  797 (Vote Outperform)
Underperform Votes:  671 (Vote Underperform)
Total Votes:  1,468
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel